{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:39Z","timestamp":1786988139840,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022184","name":"Institut Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178909","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:53:59Z","timestamp":1777478039000},"page":"178909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Apilimod in oncology: From non-malignant origins to emerging anti-cancer potential"],"prefix":"10.1016","volume":"1025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-1350","authenticated-orcid":false,"given":"C.","family":"Evrard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"G\u00fcndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Heuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178909_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314416120","article-title":"Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy","volume":"120","author":"Bao","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178909_bib3","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1093\/brain\/awae109","article-title":"Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial","volume":"147","author":"Babu","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2026.178909_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cells10010030","article-title":"The PIKfyve inhibitor apilimod: a double-edged sword against COVID-19","volume":"10","author":"Baranov","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178909_bib5","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1242\/jcs.01517","article-title":"Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles","volume":"117","author":"Berwick","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2026.178909_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/tra.12525","article-title":"PIKfyve activity regulates reformation of terminal storage lysosomes from endolysosomes","volume":"18","author":"Bissig","year":"2017","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2026.178909_bib7","first-page":"53","article-title":"Drug evaluation: Apilimod, an oral IL-12\/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency","volume":"10","author":"Billich","year":"2007","journal-title":"Idrugs"},{"key":"10.1016\/j.ejphar.2026.178909_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.ibd.0000225337.14356.31","article-title":"A phase 1\/2A trial of STA 5326, an oral interleukin-12\/23 inhibitor, in patients with active moderate to severe Crohn's disease","volume":"12","author":"Burakoff","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2026.178909_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.chembiol.2013.05.010","article-title":"PIKfyve, a class III PI kinase, is the target of the small molecular IL-12\/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling","volume":"20","author":"Cai","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejphar.2026.178909_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","article-title":"Targeting PIKfyve-driven lipid metabolism in pancreatic cancer","volume":"642","author":"Cheng","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178909_bib48","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1038\/s41467-024-48931-9","article-title":"PIKfyve, expressed by CD11c-positive cells, controls tumor immunity","volume":"15","author":"Choi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178909_bib11","doi-asserted-by":"crossref","first-page":"C366","DOI":"10.1152\/ajpcell.00104.2016","article-title":"Active vacuolar H+-ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency","volume":"311","author":"Compton","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2026.178909_bib12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3324\/haematol.2019.222729","article-title":"Identification of PIKfyve kinase as a target in multiple myeloma","volume":"105","author":"de Campos","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2026.178909_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1600-0854.2009.00915.x","article-title":"PIKfyve regulation of endosome-linked pathways","volume":"10","author":"de Lartigue","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2026.178909_bib14","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-24-1757","article-title":"Concurrent inhibition of the RAS-MAPK pathway and PIKfyve is a therapeutic strategy for pancreatic cancer","volume":"85","author":"Deliberty","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178909_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mam.2006.08.005","article-title":"Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy","volume":"27","author":"Eskelinen","year":"2006","journal-title":"Mol. Aspect. Med."},{"issue":"14","key":"10.1016\/j.ejphar.2026.178909_bib51","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/cells11142183","article-title":"Crucial role of oncogenic KRAS mutations in apoptosis and autophagy regulation: therapeutic implications","volume":"11","author":"Ferreira","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178909_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1083\/jcb.143.1.65","article-title":"Fab1p is essential for PtdIns(3)P 5-kinase activity and the maintenance of vacuolar size and membrane homeostasis","volume":"143","author":"Gary","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178909_bib17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","article-title":"Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell Non-Hodgkin lymphoma","volume":"129","author":"Gayle","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.178909_bib18","first-page":"4119","article-title":"Phase 1 clinical safety, pharmacokinetics and activity of apilimod dimesylate (LAM-002A)","volume":"130","author":"Harb","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178909_bib49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","article-title":"PIKFYVE inhibition mitigates disease in models of diverse forms of ALS","volume":"186","author":"Hung","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178909_bib19","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1152\/ajpendo.00030.2013","article-title":"Muscle-specific Pikfyve gene disruption causes glucose intolerance, insulin resistance, adiposity, and hyperinsulinemia but not muscle fiber-type switching","volume":"305","author":"Ikonomov","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2026.178909_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2009.03.063","article-title":"YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes","volume":"382","author":"Ikonomov","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.178909_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.embor.7401155","article-title":"A selective PIKfyve inhibitor blocks PtdIns(3,5)P2 production and disrupts endomembrane transport and retroviral budding","volume":"9","author":"Jefferies","year":"2008","journal-title":"EMBO Rep."},{"issue":"34","key":"10.1016\/j.ejphar.2026.178909_bib46","doi-asserted-by":"crossref","first-page":"20803","DOI":"10.1073\/pnas.2007837117","article-title":"Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2","volume":"117","author":"Kang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178909_bib22","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.devcel.2021.05.010","article-title":"Glucose starvation induces autophagy via ULK1-mediated activation of PIKfyve in an AMPK-dependent manner","volume":"56","author":"Karabiyik","year":"2021","journal-title":"Dev. Cell"},{"issue":"10","key":"10.1016\/j.ejphar.2026.178909_bib47","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/tra.12199","article-title":"PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages","volume":"15","author":"Kim","year":"2014","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2026.178909_bib23","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/art.34339","article-title":"A phase IIa randomized trial of apilimod mesylate in rheumatoid arthritis","volume":"64","author":"Krausz","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2026.178909_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00975-21","article-title":"Synergistic block of SARS-CoV-2 infection by combined drug inhibition of PIKfyve kinase and TMPRSS2 protease","volume":"95","author":"Kreutzberger","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2026.178909_bib25","doi-asserted-by":"crossref","first-page":"12432","DOI":"10.1021\/acs.jmedchem.3c00912","article-title":"Discovery of a first-in-class degrader for the lipid kinase PIKfyve","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178909_bib26","article-title":"APY0201 represses tumor growth through inhibiting autophagy in gastric cancer cells","volume":"2022","author":"Li","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejphar.2026.178909_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007290","article-title":"PIKfyve regulates melanosome biogenesis","volume":"14","author":"Liggins","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejphar.2026.178909_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/BJ20130644","article-title":"PIKfyve is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle","volume":"455","author":"Liu","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2026.178909_bib29","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1021\/acs.jmedchem.4c02531","article-title":"Development of a second-generation in vivo chemical probe for PIKfyve","volume":"68","author":"Min","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178909_bib30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s10637-014-0147-9","article-title":"Phase I study of CEP-11981 in advanced cancer","volume":"32","author":"Pili","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2026.178909_bib31","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s43018-021-00237-1","article-title":"Autophagy inhibition by targeting PIKfyve potentiates immune checkpoint blockade in prostate cancer","volume":"2","author":"Qiao","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejphar.2026.178909_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ibd.21159","article-title":"Randomized trial of apilimod mesylate in Crohn's disease","volume":"16","author":"Sands","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178909_bib52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41568-019-0137-5","article-title":"Eliminating protective autophagy in KRAS-mutant cancers","volume":"19","author":"Seton-Rogers","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2026.178909_bib33","doi-asserted-by":"crossref","first-page":"D927","DOI":"10.2741\/1101","article-title":"Regulating GLUT4 vesicle dynamics by phosphoinositide kinases and phosphoinositide phosphatases","volume":"8","author":"Shisheva","year":"2003","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejphar.2026.178909_bib34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/MCB.19.1.623","article-title":"Cloning and characterization of a novel phosphoinositide kinase","volume":"19","author":"Shisheva","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178909_bib35","doi-asserted-by":"crossref","first-page":"C436","DOI":"10.1152\/ajpcell.00105.2012","article-title":"Functional dissociation between PtdIns(3,5)P2 and PtdIns5P","volume":"303","author":"Sbrissa","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2026.178909_bib36","article-title":"Apilimod arrests PtdIns(3,5)P2 and PtdIns5P synthesis","volume":"13","author":"Sbrissa","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178909_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cellbi.2008.01.006","article-title":"PIKfyve: partners, significance, debates and paradoxes","volume":"32","author":"Shisheva","year":"2008","journal-title":"Cell Biol. Int."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178909_bib50","doi-asserted-by":"crossref","first-page":"jcs262236","DOI":"10.1242\/jcs.262236","article-title":"PIKFYVE inhibition induces endosome- and lysosome-derived vacuole enlargement via ammonium accumulation","volume":"138","author":"Uwada","year":"2025","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2026.178909_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1083\/jcb.200107069","article-title":"Roles of PI3Ks in phagosome formation and maturation","volume":"155","author":"Vieira","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178909_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035069","article-title":"Apilimod inhibits IL-12 and IL-23 in psoriasis","volume":"7","author":"Wada","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178909_bib40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2006-04-019398","article-title":"STA-5326 inhibits Th1 response","volume":"109","author":"Wada","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178909_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41419-024-06423-0","article-title":"PIKfyve inhibition reveals role for p38 MAPKs in endolysosomal fission","volume":"15","author":"Wible","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.178909_bib42","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/cells13110953","article-title":"Inhibition of PIKfyve leads to lysosomal disorders via mTOR dysregulation","volume":"13","author":"Xia","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178909_bib43","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.7150\/thno.41378","article-title":"IL-23, but not IL-12, in inflammation-mediated bone disorders","volume":"10","author":"Xu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.178909_bib44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion in pancreatic cancer","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:56:58Z","timestamp":1779001018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0014299926003912"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178909","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apilimod in oncology: From non-malignant origins to emerging anti-cancer potential","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178909"}}